2008-07-24 23:28:25 -

- PharMerica Corporation (NYSE:PMC) announced the results of today's 2008 annual meeting of stockholders.

At the annual meeting of stockholders, W. Robert Dahl, Jr. was elected to the Board of Directors. Mr. Dahl has served as Vice President of Strategic Business Development and Vice Chairman of the Board of Directors of Golden Pond Healthcare, Inc. since May 15, 2007.

From April 1999 until June 2006, he served as the head of Global Healthcare for the Carlyle Group, a leading private equity firm with over $50 billion of equity under management, where he was responsible for the firm's investments in the healthcare field. Prior to Carlyle, Mr. Dahl served as co-head of healthcare investment banking in North America at Credit Suisse First Boston. He is also a director of Slate Pharmaceuticals, Inc., Amkai LLC and Ika Systems Company.

Also elected to serve on the Board of Directors until the annual meeting of stockholders in 2009 were current directors Gregory S. Weishar, Thomas P. Mac Mahon, Frank E. Collins, Esq., Dr. Thomas P. Gerrity, Daniel N. Mendelson, and Dr. Robert A. Oakley. Stockholders also ratified the appointment of PricewaterhouseCoopers as the Company's independent auditor for the year ending December 31, 2008, and voted to approve an amendment to the Company's 2007 Omnibus Incentive Plan.

About PharMerica Corporation

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. As of March 31, 2008, PharMerica operated 109 institutional pharmacies in 40 states. PharMerica's customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to 88 long-term care hospitals. PharMerica services 97 of the top 100 markets in the United States.

From time to time, PharMerica Corporation makes "forward-looking statements," as defined within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties, contingencies and other factors that could cause results, performance or achievements to differ materially from those anticipated. Forward-looking statements include, among other things, statements relating to the Company's current and expected financial results, overall economic, financial and political conditions, industry trends, as well as other especially relevant risks as detailed in the Company's filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. The Company assumes no obligation to update the information contained in this press release.

PharMerica Corporation
Michael J. Culotta, 502-627-7475
Executive Vice President and Chief Financial Officer